IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Here's Why Investors Should Retain McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
Allscripts to Fortify Middle East Foothold With New Project
by Zacks Equity Research
Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.
Here's Why Investors Should Bet on Cooper Companies (COO) Now
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.
Here's Why Investors Should Bet on Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical's (MMSI) upbeat guidance for 2019 is indicative of the company's brighter prospects.
Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
by Zacks Equity Research
Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.
Here's Why You Should Invest in AngioDynamics Stock Now
by Zacks Equity Research
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
Here's Why Momentum Investors Will Love Idexx Laboratories (IDXX)
by Zacks Equity Research
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.
Bright Near-Term Outlook for Medical Instruments Industry
by Zacks Equity Research
Growing medical awareness and economic prosperity have been enhancing the uptake of medical instruments in the emerging economies.
IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View
by Zacks Equity Research
IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 8.89% and 0.69%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
ZBH & IDXX Q4 Earnings on Feb 1: Here are the Key Predictions
by Zacks Equity Research
The global medical device space is passing through a rewarding phase for a considerable period of time in terms of research and development (R&D) plus regulatory progress.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Idexx (IDXX) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Idexx Laboratories (IDXX) Q3 Earnings Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.14% and -0.03%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
IDEXX Laboratories (IDXX) Beats on Q3 Earnings, EPS View Up
by Zacks Equity Research
IDEXX Laboratories' (IDXX) stellar performance in Q3 reflects strong sales at the CAG business.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.
Idexx Laboratories (IDXX) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.
IDEXX Gains Ground on Solid CAG Business Amid Forex Woes
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.
Why Is Idexx (IDXX) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
Nasdaq ETF Hits New Highs: 5 Stocks Up More Than 50%
by Sweta Killa
Though most of the stocks in the Nasdaq ETF portfolio delivered strong returns so far this year, a few were the real stars, having gained more than 50%.